62 articles for J Yuan
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.
Novartis Institutes For Biomedical Research
Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model.
Shanghai Hengrui Pharmaceutical
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
The Hong Kong Polytechnic University
Structure-based design and synthesis of bicyclic fused-pyridines as MEK inhibitors.
Shanghai Hengrui Pharmaceutical
Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.
Shanghai Hengrui Pharmaceutical
Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
Pfizer
Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: Molecular docking simulation and structure-activity relationship analysis.
East China University of Science and Technology
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
TBA
1-Phenyl-3-(aminomethyl)pyrroles as potential antipsychotic agents. Synthesis and dopamine receptor binding.
Neurogen
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.
Vitae Pharmaceuticals
1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.
Novartis Institutes For Biomedical Research
Design, synthesis, and biological evaluation of a series of new anthraquinone derivatives as anti-ZIKV agents.
Sun Yat-sen University
Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one derivatives as novel FXIa inhibitors.
Puchuang Pharmaceutical Technology (Tianjin) Co., Ltd
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK).
China Pharmaceutical University
Design, synthesis, and biological evaluation of novel 2'-methyl-2'-fluoro-6-methyl-7-alkynyl-7-deazapurine nucleoside analogs as anti-Zika virus agents.
Guangzhou Institutes of Biomedicine and Health
The design, preparation and SAR of novel small molecule sodium (Na(+)) channel blockers.
Arqule
Design, synthesis, and pharmacological evaluation of sinomenine derivatives on rings A and C: Novel compounds screening for aplastic anemia targeting on cytotoxic T lymphocyte.
Peking Union Medical College
Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC.
Chongqing Medical University
Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.
Pfizer
N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration.
Pfizer
2-Phenyl-4(5)-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]imidazole. A highly selective antagonist at cloned human D4 receptors.
Neurogen
Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
Hebei Medical University
A novel necroptosis inhibitor-necrostatin-21 and its SAR study.
Chinese Academy of Sciences
Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease.
Vitae Pharmaceuticals
Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold.
Shanghai Hengrui Pharmaceutical
Arylamino containing hydroxamic acids as potent urease inhibitors for the treatment of Helicobacter pylori infection.
Jishou University
Development of a high affinity and stereoselective photoaffinity label for the D-1 dopamine receptor: synthesis and resolution of 7-[125I]iodo-8-hydroxy-3-methyl-1-(4'-azidophenyl)-2,3,4,5-tetrahydro- 1H-3-benzazepine.
Research Biochemicals
Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
Hebei Medical University
Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.
Novartis Institutes For Biomedical Research
Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
The Institute of Cancer Research: Royal Cancer Hospital
2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
Pfizer
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
Bristol-Myers Squibb
Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
Merck Sharp & Dohme
New insights into homopiperazine-based 5-HT1A/5-HT7R ligands: synthesis and biological evaluation.
University of Orleans
Structure of the Acinetobacter baumannii dithiol oxidase DsbA bound to elongation factor EF-Tu reveals a novel protein interaction site.
University of Queensland
Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
California Institute of Technology
5 oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives as CaMKII kinase inhibitors for treating cardiovascular diseases
Sanofi
In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
Hoechst Marion Roussel
In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.
Merck Research Laboratories
Enhanced ligand affinity for receptors in which components of the binding site are independently mobile.
University of Sheffield